What is B. Riley’s Forecast for VNDA FY2025 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at B. Riley issued their FY2025 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research note issued on Tuesday, November 4th. B. Riley analyst M. El-Saadi anticipates that the biopharmaceutical company will post earnings of ($2.08) per share for the year. B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. B. Riley also issued estimates for Vanda Pharmaceuticals’ Q4 2025 earnings at ($0.74) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.92 EPS and FY2029 earnings at $1.59 EPS.

Several other brokerages have also weighed in on VNDA. Cantor Fitzgerald cut their price objective on shares of Vanda Pharmaceuticals from $13.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Vanda Pharmaceuticals Trading Down 0.7%

Vanda Pharmaceuticals stock opened at $4.41 on Friday. The company has a market cap of $260.62 million, a PE ratio of -3.11 and a beta of 0.78. Vanda Pharmaceuticals has a 1 year low of $3.81 and a 1 year high of $5.70. The company’s 50-day moving average is $4.92 and its two-hundred day moving average is $4.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The firm had revenue of $56.26 million during the quarter, compared to analyst estimates of $58.73 million. Vanda Pharmaceuticals had a negative return on equity of 16.44% and a negative net margin of 39.70%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 220.0% in the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after acquiring an additional 1,470,898 shares in the last quarter. Nuveen LLC bought a new position in Vanda Pharmaceuticals in the first quarter valued at approximately $2,022,000. Marshall Wace LLP boosted its holdings in shares of Vanda Pharmaceuticals by 945.9% in the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock valued at $2,227,000 after buying an additional 426,620 shares during the period. Krensavage Asset Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 35.9% in the second quarter. Krensavage Asset Management LLC now owns 1,024,883 shares of the biopharmaceutical company’s stock valued at $4,837,000 after buying an additional 270,502 shares during the period. Finally, Stonepine Capital Management LLC increased its position in shares of Vanda Pharmaceuticals by 611.3% during the second quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock worth $1,180,000 after acquiring an additional 214,852 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.